Kodiak’s KSI-101 Delivers Promising Data in Retinal Disease Study
PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data...
CRANBURY, New Jersey, September 11, 2025 — Biocon Limited has inaugurated its first U.S. manufacturing facility in Cranbury, New...
